DRKS00000416已完成4 期
Efficacy and safety of Mutaflor (R) (Escherichia coli strain Nissle 1917) in patients with irritable bowel syndrome
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years(—)
- 性别
- All
入选标准
- •1. Age 18 - 65 years
- •2. At least 12 week, which need not be consecutive, in the preceding 12 months of abdominal discomfort or pain that has 2 of 3 features:
- •- relieved with defecation; and/or
- •- Onset associated with a change in frequency of stool; and/or
- •- Onset associated with a change in form (appearance) of stool (Irritable bowel syndrome confirmed according to the Rome-II-criteria)
- •3. Total points in Kruis score = 26 points
- •4. At least three of the following symptoms are present at entry into the study:
- •diarrhoea, constipation, urgency of defecation, abdominal pain, meteorism, flatulence, tenesmus, tender on pressure, abdominal sounds, nausea, satiety. 5. Informed consent given in writing and signed
排除标准
- •General Exclusion Criteria:
- •1. Participation in a clinical study within the last 30 days
- •2. Simultaneous participation in another clinical study
- •3. Lack of cooperation
- •4. Limited legal capacity of patient
- •5. Women of childbearing age without sufficient contraceptive protection
- •6. Pregnancy or breastfeeding
- •7. Dependence on alcohol, medical drugs or other drugs
- •8. Severe mental disorders or depressions within the last two years
- •9. Anamnestic data indicating an organic disease (red flags”) and requiring further diagnostic tests
- •10. Oher reasons running counter to inclusion of the patient in the study in the investigator's view
- •Anamnestic Exclusion Criteria
- •1. Lack of complaints
- •2. Inflammatory bowel disease
- •3. Infectious colitis
- •4. Carcinoma
- •5. Celiac disease
- •6. Intolerance of lactose
- •7. Use of laxatives (i.e. regularly on at least 5 days per week)
- •8. Functional diarrhoea (i.e. more than ¾ of all defecations in the last 3 months were either thick pasty, thin pasty or watery)
- •9. Chronic constipation (i.e. regular need of intense pressing to achieve a painful defecation without using pharmacological, chemical or mechanical aids)
- •10. Serious operation of the colon (colectomy, partial or total)
- •11. Present intake of antibiotics
- •12. Intake of Mutaflor within the last 3 months
研究者
相似试验
进行中(未招募)
不适用
Evaluation of the efficacy and safety of Effentora® tablets for painful procedures requiring analgesia in patients receiving already opioids for their background pain.EUCTR2012-005032-29-FRAssociation Bigorre Douleurs60
已完成
4 期
Efficacy and Safety of Enteral Erythromycin Estolate in Combination with Intravenous Metoclopramide versus Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients with Enteral Feeding Intolerance: A Randomized Pilot Studyfeeding intolerancemechanically ventilated patientprokineticfeeding intolerancemechanically ventilated patientserythromycin estolategastric residual volumeTCTR20171004004Siam University30
尚未招募
不适用
A Clinical trial to Study the effect of a herbal ointment on joint paiCTRI/2010/091/000455Hamdard National Foundation New Delhi100
终止
2 期
A Safety & Efficacy Study of BGS649 in Women With Refractory EndometriosisPelvic Pain Associated With Refractory EndometriosisNCT01116440Mereo BioPharma27
已完成
1 期
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus PneumoniaePneumococcal InfectionsPneumoniaNCT02583373Combioxin SA19
